COMPOSITION FOR THE TREATMENT OF COVID-19 INFECTION, AND A METHOD OF TREATMENT

Abstract

Oral composition and a method for the treatment of coronaviruses infections in humans and animals. The method includes the steps of administering orally a methionine cleaving-enzyme; administering orally or parentally a protease inhibitor; and orally administering pyridoxal-L-phosphate in a fluid.

Claims

1. A method for treating coronavirus infection in living beings, the method comprising the steps of: administering, orally, a composition comprising methioninase enzyme; and administering, orally, a fluid comprising pyridoxal-L-phosphate.

2. The method according to claim 1, wherein the method further comprises the steps of: upon administering the methioninase enzyme, administering, orally or parentally, a protease inhibitor.

3. The method according to claim 1, wherein the methioninase enzyme is a recombinant L-methionine α-deamino-γ-mercaptomethane lyase.

4. The method according to claim 2, wherein the protease inhibitor is orally administered, the protease inhibitor is a serine- or cysteine-protease inhibitor.

5. The method according to claim 4, wherein a combination of the serine- and cysteine-protease inhibitors are administered.

6. The method according to claim 5, wherein the serine protease inhibitor is Carmostat mesylate and the cysteine protease inhibitor is E-64d.

7. The method according to claim 2, wherein the protease inhibitor is parentally administered, the protease inhibitor is a serine- or cysteine-protease inhibitor.

8. The method according to claim 7, wherein a combination of the serine- and cysteine-protease inhibitors are administered.

9. The method according to claim 1, wherein the composition further comprises flavors, sweeteners, and binders.

10. The method according to claim 1, wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.

11. A method for treating coronavirus infection in living beings, the method comprises the steps of: administering, orally, a composition comprising methioninase enzyme and an oral protease inhibitor; and administering, orally, a fluid comprising pyridoxal-L-phosphate.

12. The method according to claim 11, wherein the methioninase enzyme is a recombinant L-methionine α-deamino-γ-mercaptomethane lyase.

13. The method according to claim 11, wherein the protease inhibitor is a serine- or cysteine-protease inhibitor.

14. The method according to claim 13, wherein a combination of the serine- and cysteine-protease inhibitors are administered.

15. The method according to claim 14, wherein the serine protease inhibitor is Carmostat mesylate and the cysteine protease inhibitor is E-64d.

16. The method according to claim 11, wherein the composition further comprises flavors, sweeteners, and binders.

17. The method according to claim 11, wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.

Description

DETAILED DESCRIPTION

[0024] Subject matter will now be described more fully hereinafter using specific exemplary embodiments. Subject matter may, however, be embodied in a variety of different forms and, therefore, covered or claimed subject matter is intended to be construed as not being limited to any exemplary embodiments set forth herein; exemplary embodiments are provided merely to be illustrative. Likewise, a reasonably broad scope for claimed or covered subject matter is intended. Among other things, for example, the subject matter may be embodied as methods and compositions. The following detailed description is, therefore, not intended to be taken in a limiting sense.

[0025] The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments. Likewise, the term “embodiments of the present invention” does not require that all embodiments of the invention include the discussed feature, advantage, or mode of operation.

[0026] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of embodiments of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises”, “comprising,”, “includes” and/or “including”, when used herein, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.

[0027] The following detailed description includes the best currently contemplated mode or modes of carrying out exemplary embodiments of the invention. The description is not to be taken in a limiting sense but is made merely for the purpose of illustrating the general principles of the invention, since the scope of the invention will be best defined by the allowed claims of any resulting patent.

[0028] Disclosed is a composition and method for the treatment of coronavirus infections in humans and animals, such as Covid-19 viral infection. The disclosed composition can be orally administered and may not require any strict dietary reductions. Not requiring parental administering can be a particular advantage of the disclosed composition and method, as in severe contagious diseases, such as covid-19 viral infections, the patients can themselves take the medicine.

[0029] Disclosed is a method for the treatment of coronavirus infections in living beings. The method includes the steps of orally administering a composition including methioninase enzyme and orally administering a fluid containing pyridoxal-L-phosphate as a cofactor. Optionally, the method may further comprise the step of orally or systemically administering a cysteine- or serine-protease inhibitor. The composition can also include phosphate-buffer saline solution.

[0030] The protease inhibitors can be serine or cysteine protease inhibitors that can be both orally and parentally administered. Preferably, in severe acute respiratory distress syndrome, the protease inhibitors can be systemically administered. Also, more than one protease inhibitor can be administered. In case of more than one protease inhibitor is administered, both taken orally, both taken parentally, one taken orally and the other taken parentally are within the scope of the present invention. Both oral or systemic administration of serine or cysteine protease inhibitors can inhibit coronavirus entry into the cells. The protease inhibitors can have a synergistic effect with the methioninase enzyme in the treatment of COVID-19 infection.

[0031] The composition including methioninase enzyme can act by lowering the serum methionine levels. It has been scientifically established that the virus-infected cells become methionine addicted. Moreover, the scientific investigations in the art had revealed that coronaviruses require their genome to be methylated, thus are methionine dependent. This novel approach for reducing the multiplication of coronaviruses and treatment of Covid-19 infection in humans and animals has not been explored yet. Additionally, inflammation is the key factor in the spread of infection which can also be the target for the methioninase enzyme since T-cells require excess methionine when activated. Therefore, the disclosed composition can target multiple pathways for decreasing the spread of coronavirus within a living being. Moreover, the disclosed combination of methioninase enzymes with protease inhibitors can have a synergistic effect in the treatment of coronavirus infection. Such a combination can be a powerful cure for patients in severe conditions and probably on life support.

[0032] Protease inhibitors, in particular the serine- and cysteine-protease inhibitors are known in the art for both oral and parental administration, and such protease inhibitors are within the scope of the present invention. Serine protease inhibitor Carmostat mesylate is commercially available that is having good oral bioavailability. E-64d is a known inhibitor of cysteine protease cathepsin B. E-64d can be given alone or in combination with Carmostat mesylate. E-64d also has good oral bioavailability.

[0033] In one exemplary embodiment, the disclosed oral composition can include a methioninase enzyme and one or more oral protease inhibitors. The methioninase enzyme can be a recombinant L-methionine α-deamino-γ-mercaptomethane lyase. The protease inhibitors can include Carmostat mesylate or E-64d, or a combination thereof. When compared with ip-rMETase, oral rMETase (“o-rMETase”) is significantly more effective than ip-rMETase, provided administration of the o-rMETase is accompanied by pyridoxal-L-phosphate (“PLP”) in drinking water.

[0034] In one exemplary embodiment, disclosed is a method of treating coronavirus infection in living beings including humans and animals. The method includes the steps of orally administering a composition including a methioninase enzyme. The method further includes the step of orally administering pyridoxal-L-phosphate in fluid, such as drinking water. The methioninase enzyme can be recombinant L-methionine α-deamino-γ-mercaptomethane lyase.

[0035] In one exemplary embodiment, disclosed is a method of treating coronavirus infection in living beings including humans and animals. The method includes the steps of orally administering a composition including a methioninase enzyme and an oral protease inhibitor. The method further includes the step of orally administering pyridoxal-L-phosphate in fluid, such as drinking water. The methioninase enzyme can be recombinant L-methionine α-deamino-γ-mercaptomethane lyase. Preferably, the protease inhibitor can be a serine or cysteine inhibitor, or a combination thereof. More preferably, the protease inhibitor can be an oral protease inhibitor, such as Carmostat mesylate and E-64d. It is to be understood that the composition can include more than one protease inhibitor of the same or a different class without departing from the scope of the present invention.

[0036] In one exemplary embodiment, disclosed is a method of treating coronavirus infection in leaving beings including humans and animals. The method includes the steps of orally administering a composition including a methioninase enzyme. The method further includes the step of orally or parentally administering a protease inhibitor. The method further includes the step of orally administering pyridoxal-L-phosphate in fluid, such as drinking water. The methioninase enzyme can be recombinant L-methionine α-deamino-γ-mercaptomethane lyase. Preferably, the protease inhibitor can be a serine or cysteine inhibitor, or a combination thereof. Preferably, the protease inhibitor can be an oral protease inhibitor, such as Carmostat mesylate and E-64d. It is to be understood that more than one protease inhibitor can be administered through different routes.

[0037] The embodiments and examples set forth herein were presented to best explain the present invention and its practical application and to thereby enable those of ordinary skill in the art to make and use the invention. However, those of ordinary skill in the art will recognize that the foregoing description and examples have been presented for the purposes of illustration and example only. The description as set forth is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of the teachings above and are intended to fall within the scope of the appended claims.